| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8281ac9f4fb11f15a5da018344453338 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0804 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-02 |
| filingDate |
2007-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f411a0496a93f34f0b80af249c356141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f65bf29c5aeab185042ca08a74824ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e8a3f3873f5921eb9f57df16e0757df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d573083ba72859de14b77d210c438b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b40147b6917e1be028f6ac2767694e8 |
| publicationDate |
2009-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090017688-A |
| titleOfInvention |
Macrocyclic Oxymil Hepatitis C Protease Inhibitor |
| abstract |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof which inhibits serine protease activity, in particular the activity of hepatitis C virus (HCV) NS3-NS4A protease. Thus, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention also relates to a pharmaceutical composition comprising said compound for administration to a patient suffering from HCV infection. The invention also relates to a method of treating HCV infection in a patient by administering a pharmaceutical composition comprising a compound of the invention.n n n Formula In n n n n n n n In Formula I,n n n All substituents are as defined herein. |
| priorityDate |
2006-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |